Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study
| Autor: | Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
Oncology Cancer Research Lung Neoplasms I-O Optimise initiative Denmark medicine.medical_treatment registry NSCLC Tyrosine-kinase inhibitor Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Pneumonectomy Lung treatment General Medicine Middle Aged Neoadjuvant Therapy Treatment Outcome Female Non small cell Adult medicine.medical_specialty Adolescent medicine.drug_class overall survival Stage iv disease History 21st Century Young Adult Internal medicine medicine Overall survival Humans Initial treatment In patient Mortality Lung cancer Aged Neoplasm Staging Retrospective Studies time trends business.industry Chemoradiotherapy Adjuvant medicine.disease respiratory tract diseases Radiation therapy SCAN-LEAF business Follow-Up Studies |
| Zdroj: | Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005–2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0–60.6%) but not squamous NSCLC (44.9–47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23–31%) but not squamous NSCLC (22–25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|